These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 26506065)
41. Platysma synkinesis in facial palsy and botulinum toxin type A. Dall'Angelo A; Mandrini S; Sala V; Pavese C; Carlisi E; Comelli M; Toffola ED Laryngoscope; 2014 Nov; 124(11):2513-7. PubMed ID: 24764160 [TBL] [Abstract][Full Text] [Related]
42. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard. Nestor MS; Ablon GR J Drugs Dermatol; 2011 Oct; 10(10):1148-57. PubMed ID: 21968665 [TBL] [Abstract][Full Text] [Related]
43. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059 [TBL] [Abstract][Full Text] [Related]
44. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study. Alimohammadi M; Andersson M; Punga AR Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053 [TBL] [Abstract][Full Text] [Related]
46. Botox® after Botox® - a new approach to treat diplopia secondary to cosmetic botulinic toxin use: case reports. Isaac CR; Chalita MR; Pinto LD Arq Bras Oftalmol; 2012; 75(3):213-4. PubMed ID: 22872208 [TBL] [Abstract][Full Text] [Related]
47. OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review. Carruthers A; Bruce S; Cox SE; Kane MA; Lee E; Gallagher CJ Aesthet Surg J; 2016 May; 36(5):591-7. PubMed ID: 26979457 [TBL] [Abstract][Full Text] [Related]
48. Botulinum toxin in facial rejuvenation: an update. Carruthers J; Carruthers A Dermatol Clin; 2009 Oct; 27(4):417-25, v. PubMed ID: 19850191 [TBL] [Abstract][Full Text] [Related]
49. The use of botulinum toxin type A in cosmetic facial procedures. Jaspers GW; Pijpe J; Jansma J Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695 [TBL] [Abstract][Full Text] [Related]
50. Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport). Dover JS Aesthet Surg J; 2017 May; 37(suppl_1):S1-S3. PubMed ID: 28388716 [No Abstract] [Full Text] [Related]
51. Botulinum toxin in men: review of relevant anatomy and clinical trial data. Keaney TC; Alster TS Dermatol Surg; 2013 Oct; 39(10):1434-43. PubMed ID: 24090254 [TBL] [Abstract][Full Text] [Related]
52. [Depressor anguli oris sign (DAO) in facial paresis. How to search it and release the smile (technical note)]. Labbé D; Bénichou L; Iodice A; Giot JP Ann Chir Plast Esthet; 2012 Jun; 57(3):281-5. PubMed ID: 22647640 [TBL] [Abstract][Full Text] [Related]
53. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Allen SB; Goldenberg NA Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727 [TBL] [Abstract][Full Text] [Related]